| Training cohort | Validation cohort | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Variable | Patients | CSF-1 expression | P | Patients | CSF-1 expression | P | ||||
 | Number | % | Low (n = 99) | High (n = 96) |  | Number | % | Low (n = 43) | High (n = 29) |  |
Age (years)* | 55.3 | 56.2 | 54.3 | 0.245 | 59.8 | 61.5 | 59.1 | 0.421 | ||
Gender | Â | Â | Â | Â | 0.987 | Â | Â | Â | Â | 0.982 |
Male | 137 | 70.3 | 70 | 67 | Â | 51 | 70.8 | 31 | 20 | Â |
Female | 58 | 29.7 | 29 | 29 | Â | 21 | 29.3 | 12 | 9 | Â |
Tumor size (cm)* | 4.7 | 4.4 | 4.9 | 0.194 | 5.2 | 4.8 | 5.8 | 0.106 | ||
TNM stage | Â | Â | Â | Â | 0.091 | Â | Â | Â | Â | 0.077 |
I + II | 134 | 68.7 | 74 | 60 |  | 56 | 77.8 | 37 | 19 |  |
III + IV | 61 | 31.3 | 25 | 36 |  | 16 | 22.2 | 6 | 10 |  |
Fuhrman grade | Â | Â | Â | Â | 0.001 | Â | Â | Â | Â | 0.007 |
1 + 2 | 122 | 62.6 | 74 | 48 |  | 49 | 68.1 | 35 | 14 |  |
3 + 4 | 73 | 37.4 | 25 | 48 |  | 23 | 31.9 | 8 | 15 |  |
Necrosis | Â | Â | Â | Â | 0.013 | Â | Â | Â | Â | 0.039 |
Absent | 150 | 76.9 | 84 | 66 | Â | 55 | 76.4 | 37 | 18 | Â |
Present | 45 | 23.1 | 15 | 30 | Â | 17 | 23.6 | 6 | 11 | Â |
ECOG PS | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
0 | 160 | 82.1 | 80 | 80 | 0.785 | 59 | 81.9 | 36 | 23 | 0.869 |
≥1 | 35 | 17.9 | 19 | 16 |  | 13 | 18.1 | 7 | 6 |  |